Comparative Efficacy And Tolerability Of Antidepressants For Major Depressive Disorder In Children And Adolescents: A Network Meta-Analysis
- ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
- Kurt D. Michael Ph.D, Professor (Creator)
- Institution
- Appalachian State University (ASU )
- Web Site: https://library.appstate.edu/
Abstract: Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies’ websites, and international registers for published and unpublished, double-blind randomised controlled trials up toMay 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fl uoxetine, imipramine, mirtazapine,nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatmentresistantdepression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. Weassessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.
Comparative Efficacy And Tolerability Of Antidepressants For Major Depressive Disorder In Children And Adolescents: A Network Meta-Analysis
PDF (Portable Document Format)
243 KB
Created on 2/6/2017
Views: 2216
Additional Information
- Publication
- Cipriani, A, Zhou, X, Michael, K., et. al. 2016. Comparative Efficacy And Tolerability Of Antidepressants For Major Depressive Disorder In Children And Adolescents: A Network Meta-Analysis. The Lancet. June 8, 2016. Version of record available online at: http://dx.doi.org/10.1016/S0140-6736(16)30385-3.
- Language: English
- Date: 2016
- Keywords
- Major depressive disorder, efficacy, tolerability, adolescents and children